Prot# 4522US/0001: A 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20mg and 40mg with that of Atorvastatin 80mg in Subjects with Acute Coronary Syndr

Project: Research project

Project Details

StatusFinished
Effective start/end date5/6/048/7/09

Funding

  • ICON Clinical Research, LLC (4522US/0001)
  • AstraZeneca Pharmaceuticals LP (4522US/0001)